Navigation Links
ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Date:9/4/2007

Transfer Paves the Way for the Phase III Clinical Development and

Commercialization of THR-100 in Developing Countries

LEUVEN, Belgium, September 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced the successful completion of the technology transfer to Bharat Biotech International Limited (Hyderabad, India) for the manufacture of THR-100, a novel variant of Recombinant Staphylokinase.THR-100 is a thrombolytic agent developed for the treatment of acute myocardial infarction (AMI or heart attack) and other vascular diseases, based on its ability to dissolve blood clots.

ThromboGenics had earlier (December 6, 2006) announced the completion of a license agreement with Bharat Biotech to manufacture, develop and commercialize THR-100 as a replacement for established thrombolytics, such as streptokinase and urokinase, in developing countries. THR-100 has completed Phase II clinical trials in Europe for treatment of AMI, and is expected to enter Phase III in India later this year.

With this announcement, ThromboGenics has completed the successful transfer of its robust, proprietary and scaled-up process for the production of THR-100, a recombinant protein. Bharat Biotech will use its manufacturing capabilities, along with technological expertise acquired from ThromboGenics, to produce clinical-grade material for upcoming clinical trials. By absorbing the THR-100 manufacturing technology at different scales, while maintaining required yield and purity, Bharat Biotech has demonstrated its ability and capacity to produce this recombinant protein with the desired performance, quality and cost-effectiveness.

Prof. Desire Collen, CEO of ThromboGenics, commented on today's announcement: "We are pleased that ThromboGenics and Bharat Biotech have successfully completed the technology transfer needed for the production of THR-100. Transfer of biopharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... from a survey of European physicians at the ... Innovation and Biological Therapies" at the Spanish Ministry ... hosted by EuropaBio and the Spanish Bioindustry Association ... Health, physicians from Spanish oncology and rheumatology societies, ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research ... Products team as Sales/Marketing Manager. Mr. Holder has over ... for the graphite industry. , “We are thrilled to ... Dave Trinkley, VP of Market and Product Development for ... in the graphite industry, along with his proven track ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... Calif., Dec. 5, 2011 OvaGene Oncology Inc., ... and commercialization of personalized gene-based diagnostics for gynecologic ... major Licensing and Collaboration Agreement with The Moffitt ... Comprehensive Cancer Center in Florida.  The agreement provides ...
... REDWOOD CITY, Calif., Dec. 5, 2011 Codexis, Inc. (Nasdaq: ... has been named Vice President and Chief Marketing Officer.  ... for the company,s corporate marketing and communications.  He will ... Officer. Mr. Bolsen is a widely recognized ...
... 2011  Immune Design Corp. announced today that Wayne ... new Chief Development Officer.  Dr. Gombotz brings a ... key leadership position at Immune Design.  He will ... therapeutic vaccine product candidates. (Logo: ...
Cached Biology Technology:OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 2OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 3Codexis Names Wes Bolsen VP and Chief Marketing Officer 2Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... delivers new insight about rapid toxin evolution in venomous snakes: ... race with opossums, a group of snake-eating American marsupials. Although ... this fact has not been factored into previous explanations for ... usually seen as a feeding, or trophic, adaptation. But new ...
... contrast agents that sneak into bacteria disguised as glucose ... sensitivity and specificity. These agents -- called maltodextrin-based imaging ... other inflammatory conditions. "These contrast agents fill the ... of bacteria in vivo and distinguish infections from other ...
... 18, 2011) Researchers from the John Theurer Cancer ... 14 cancer-related studies during the recently concluded American Society ... June 3 7, 2011 in Chicago. The studies ... treatment outcomes, and patient quality of life issues. ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3New contrast agents detect bacterial infections with high sensitivity and specificity 2New contrast agents detect bacterial infections with high sensitivity and specificity 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6